AI adoption in workplace nearly doubles: Gallup
The use of artificial intelligence (AI) in the workplace has nearly doubled over the past two years, according to a new survey.
A Gallup study, released Monday, found the share of U.S. employees who say they have used AI in their role a few times a year nearly doubled from 21 percent to 40 percent in the past two years.
More frequent use of AI at work, defined as a few times a week or more by Gallup, also increased from 11 percent to 19 percent since Gallup first measured in 2023.
In the past year alone, daily use of AI doubled from 4 percent to 8 percent, Gallup found.
The findings come amid a broader push to incorporate AI into various industries to boost efficiency and workflow. Various studies show an increasing number of workers are harnessing AI tools at work.
While more workers are embracing the emerging technology, concerns have been raised about its threat to their jobs being altered or eliminated as a result.
Although workplace AI use is increasing, Gallup found employees are no more likely to see themselves replaced by the technology soon. About 15 percent of employees say it is very or somewhat likely that automation, robots or AI will eliminate their job within the next five years, according to the survey.
And only 16 percent strongly agreed the AI tools for their organization are useful for their work.
Gallup further found AI adoption increased primarily among white-collar roles, with 27 percent of white-collar employees reporting frequent use of AI at work. This is a 12 percent increase since last year, Gallup said.
Meanwhile, production and front-line workers reported slightly less frequent AI use from 2023, decreasing from 10 percent to 9 percent this year.
Several employees reported they are using AI without guardrails or guidance, Gallup said. About 44 percent of employees surveyed said their workplace started integrated AI, but only 22 percent said they have not received a clear plan or strategy for this.
The quarterly Gallup workforce study was conducted with self-administered web surveys among a random sample of adults working full-time and part-time for organizations in the United States. The sampling of error varied based on different topics and time frames, Gallup said.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a directed share issue of approximately MSEK 30
STOCKHOLM, June 17, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced it has signed a collaboration and license agreement with Castle Biosciences (NASDAQ: CSTL), a US-based leader in molecular diagnostics. The initial goal of the collaboration is to develop a test that predicts flares in patients diagnosed with atopic dermatitis (AD). The method will be based on SciBase's EIS technology and specifically, Nevisense, inclusive of both the desktop and point-of care devices. In connection with the collaboration and license agreement, SciBase intends to carry out a directed share issue of approximately SEK 30 million, of which Castle Biosciences has undertaken to subscribe for shares corresponding to a total amount of approximately SEK 19 million. The subscription price in the directed share issue corresponds to SEK 0.40 per share. Additional information regarding the directed share issue will be announced through a separate press release in connection with this press release. Under the collaboration and license agreement, the Companies will jointly explore and develop various clinical indications related to dermatologic diseases. SciBase's initial territory will be the EU, Switzerland, United Arab Emirates, Japan and South Korea, while Castle Biosciences' initial territory will be North America. Assuming development success, SciBase will receive a single-digit royalty percentage on the Castle gross margin as well as a low double-digit percentage mark-up on product sales to Castle. SciBase will also receive a milestone payment of 5 million U.S. dollars when Castle sales reach 50 million U.S. dollars annually. While the development agreement calls for sharing of development costs, SciBase will be deferring its clinical development costs for the initial indication of pre-symptomatically predicting flares in patients diagnosed with atopic dermatitis, with reimbursement being made from future royalty and milestone payments. "This collaboration with Castle Biosciences is exciting for SciBase," said Pia Renaudin, CEO of SciBase. "It will accelerate the use of Nevisense within the skin barrier health market. It will rapidly broaden our already existing clinical studies pipeline by increasing the number of studies, ultimately speeding up access to more effective therapies for patients with skin barrier dysfunction. We are also pleased to welcome Castle as a shareholder in SciBase." "We are excited to expand our commitment to the dermatologic community, clinicians and patients alike, with the signing of this agreement," said Derek Maetzold, CEO of Castle Biosciences. "Atopic dermatitis is a disease that impacts a significant number of lives, worldwide. We are excited about this opportunity to work with SciBase to develop a test that could improve the management of patients diagnosed with this disease, and potentially other dermatologic diseases. We believe this is a good fit for us, with our existing commercial portfolio of tests in skin cancers, as well as our pipeline test in development for use in patients diagnosed with moderate-to-severe AD who are seeking systemic treatment - the majority of which are managed by the same dermatological clinician." In connection with the collaboration and license agreement, SciBase intends to carry out a directed share issue of approximately SEK 30 million. The subscription price in the directed share issue corresponds to SEK 0.40 per share. Castle Biosciences has undertaken to subscribe for 47,886,950 shares in the directed share issue, corresponding to approximately SEK 19 million. Through the directed share issue, Castle Biosciences is becoming one of SciBase's largest shareholders. Additional information regarding the directed share issue will be announced through a separate press release in connection with this press release and will be available at: About Skin Barrier Dysfunction Skin barrier dysfunction is a key contributing factor to a wide range of skin disorders - including atopic dermatitis, psoriasis, ichthyosis, rosacea, and even acne. Estimates suggest that over 500 million people globally are affected by conditions in which skin barrier impairment plays a central role. Estimated global prevalence by condition includes: Atopic dermatitis (eczema): ~223 million1) Psoriasis: ~125 million2) Rosacea: ~400 million (many with impaired barrier function)3) Additionally, a wide range of cosmetic and subclinical skin concerns-such as dryness, irritation, and product sensitivity-are linked to mild or temporary skin barrier disruption. These milder forms may affect over a billion people globally at some point in their lives. This information is information that SciBase Holding AB is obliged to make public pursuantto the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 22.30 CEST on June 16, 2025. About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. For further information please contact: Pia Renaudin, CEO,Phone. +46732069802E-mail: Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ)Tel: +46 (0)73 856 42 65E-mail: certifiedadviser@ About SciBase and NevisenseSciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at For press releases and financial reports visit: -------------------------------------------------------------------------------------- 1Global Report on Atopic Dermatitis - 2https:// 3https:// This information was brought to you by Cision The following files are available for download: SciBase PR - collaboration - final Nevisense Go Nevisense new software 2025 with curve EU View original content:
Yahoo
20 minutes ago
- Yahoo
SoftBank Sells T-Mobile Stake for $4.8 Billion to Fund AI Push
(Bloomberg) -- SoftBank Group Corp. raised around $4.8 billion through a sale of T-Mobile US Inc. shares, a move that helps fund the Japanese company's grandiose plans for artificial intelligence. As Part of a $45 Billion Push, ICE Prepares for a Vast Expansion of Detention Space Security Concerns Hit Some of the World's 'Most Livable Cities' As American Architects Gather in Boston, Retrofits Are All the Rage The Tokyo-based technology group sold 21.5 million T-Mobile shares for $224 each — pricing at the bottom of the $224 to $228 range — in an unregistered overnight block sale, according to the final terms of the deal seen by Bloomberg News. The offering — which Bloomberg reported earlier — represents a discount of 3% to T-Mobile US's Monday closing price of $230.99 per share. SoftBank is ramping up investments aimed at making AI reasoning superior to humans': It plans to put down as much as $30 billion in OpenAI and is also working with the ChatGPT creator to ferry hundreds of billions of dollars into data centers and related infrastructure in the US and around the world. Its original plans for debt financing had snagged on uncertainties around US tariffs. T-Mobile shares fell 3.9% in extended trading. They have climbed 4.7% in the year to date through Monday's close. SoftBank's shares climbed as much as 2.3% in early trading in Tokyo. The deal is the biggest US share sale since Toronto-Dominion Bank sold a $13.1 billion stake in brokerage firm Charles Schwab Corp. in February. Sales of new and existing shares in US-listed companies reached $91.4 billion in the year to date, up from $75.9 billion in the same period a year ago, data compiled by Bloomberg show. The T-Mobile stake sale would be the latest example of SoftBank founder Masayoshi Son tapping past investment successes — such as an early bet on Alibaba Group Holding Ltd. that's yielded thousands-fold returns — to fund new ventures. SoftBank received T-Mobile shares with the completion of the US telecom company's $26.5 billion acquisition of Sprint Corp. in April 2020. Later that year, SoftBank substantially reduced its stake in T-Mobile via a $21 billion deal that helped pay for a record buyback of SoftBank's shares. The stake offered represents about 1.9% of T-Mobile's outstanding shares, according to Bloomberg calculations. SoftBank owned 85.4 million shares or 7.5% of T-Mobile as of March 31, according to its annual report. Deutsche Telekom AG is T-Mobile's largest shareholder with a 59% stake, according to a June 12 filing with the US Securities and Exchange Commission. Bank of America Corp. was sole bookrunner for the deal, the terms show. --With assistance from Min Jeong Lee. (Updates share reaction and adds background from the first paragraph.) Ken Griffin on Trump, Harvard and Why Novice Investors Won't Beat the Pros American Mid: Hampton Inn's Good-Enough Formula for World Domination How a Tiny Middleman Could Access Two-Factor Login Codes From Tech Giants The Spying Scandal Rocking the World of HR Software US Allies and Adversaries Are Dodging Trump's Tariff Threats ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Digital Trends
30 minutes ago
- Digital Trends
Forget Pro Max iPhones and Ultra Samsungs, the best phone I've used in years is the humble Pixel 9
A few weeks ago, I returned to my Google Pixel 9 to test Gemini's next-gen AI features. It was hard letting go of the OnePlus 13, arguably one of the most rewarding phones out there. Plus, given the 'Pixel history,' I had prepared myself for a bumpy ride, just like the Pixel 8, and the Pixel 7 before it. To my surprise, the Pixel 9 fared a lot better. It feels snappier on Android 16, takes sharp pictures, and lasts all day easily. The only thing pulling it down? The sporadic bad apps and updates. It's not enough to consider a replacement, but it's certainly frustrating in bits and pieces. Recommended Videos Overall, I think this is the most refined Pixel that Google has made to date. And with the regular discounts that often shave hundreds of dollars from its official asking price, there is little reason to look elsewhere. But ultimately, it's what you get from the phone that really made me question uber-expensive devices like the Samsung Galaxy S25 Ultra or iPhone 16 Pro Max, which cost over 50% as much. Feels great, fixed flaws If I were to put a cumulative number on my usage spell for the Pixel 9, it falls close to six months. I've never put a case on the phone, and the only protection I applied on it was a thin screen guard. Yes, despite Corning's claims, the Gorilla Glass Victus 2 shield can't survive a pocket loaded with keys, coins, thumb drives, and candies. The shiny glass rear shell is no different. On the other hand, the metallic frame with a satin finish has held up pretty well. There are no scuff marks on it, and I haven't noticed any other forms of hardware hiccups so far. This phone feels every bit as premium as your average Samsung Galaxy or iPhone, and you really need to feel it in your hands to get a grasp of the fantastic build. Google got the ergonomics right on this one, even though it's not the lightest phone out there. It is, however, instantly recognizable and doesn't suffer from the identity crisis that you will find on Samsung and Apple devices that have looked virtually identical for the past few generations. I've had my friends and co-working buddies repeatedly telling me that the Pixel 9 feels like the premium device Google always intended to make. The only problem? It runs hot, and in unpredictable spots. It handled games well, but got warm while using Maps for navigation. The banking app kept crashing and working up the phone's thermal hardware, while long edits in Adobe Express and the Instagram Edits app sailed smoothly. A quick look at the Google Community forum suggests that it's due to poor app patches and optimization from developers, but it's weird to notice these stutters. One of my biggest issues with the Pixel 9 was the slow image processing in the camera app last year. I can confirm that the woe is gone. I've extensively tested hi-res and portrait capture modes, and I could see the final image in less than a second. There's no lag in switching from the viewfinder to the image preview, and even with images that required manual frame adjustment, there was no unwanted delay at any stage. Aside from those sporadic jitters, everything worked flawlessly atop the stable build of Android 16. My secondary driver for personal communication is an iPhone 16 Pro Max, which is expectedly fluid, but doesn't have the same snappy feel as the Pixel 9. Oh, and I absolutely love the new predictive back gesture introduced in Android 16. Leaving a mark, where it matters Let's address the elephant in the room. The Tensor G4 processor. For an average smartphone user who is not too deep into demanding games or obsessed with maxing out in-game graphics settings, the Pixel 9 will serve you just fine. The hiccups with a slow camera capture have been fixed, and I didn't feel the need to boot in safe mode to find bad apps. The day-to-day activities, in a nutshell, fare smoothly. The numbers defy logic, however. Talking about benchmark comparisons, well, the Tensor G4 scores nearly half as much as the Qualcomm Snapdragon 8 Elite in phones like the Galaxy S25, and even lower than Apple's A18 Pro inside the iPhone 16 series. It's not even a substantial upgrade over the Pixel 8's Tensor G3 processor. So, is the Pixel 9 a laggard? Yes. Is the real-life experience reflective of those tests? No. Making calls, texting all day, watching social videos, letting off some steam in Diablo: Immortal, snapping pictures, and editing short clips for Instagram. All these activities are handled just fine. At this point, we also need to change the definition of 'processing power.' A healthy bunch of experiences on the Pixel 9 are now powered by AI. And more specifically, the on-device workflows running the Gemini Nano model, thanks to the on-board AI accelerator chip referred to as a TPU. On-device AI processing now lends a hand with video rendering, translation, scam detection in calls and messages, accessibility features like talkback, Smart Reply in Gboard keyboard, audio summarization, and even media editing. Remember Magic Editor and Pixel Screenshots? Yeah, all that, and more. How does it stand out? You see, AI is now a transformative part of the Android experience, and the Pixels get the first (often exclusive) dibs on it. And it's not just the vanilla experience and quick access to OS upgrades that matter here, but also those exclusive Pixel Feature Drop updates that add unique features to Google's phones. Ever since the Pixel 9 series was released, it has received features like audio noise eraser for videos, underwater photography mode, theft detection lock, private space, AI-powered call screening, live call transcripts, expressive captions, Identity Check, and more. Android 16 — riding atop the Pixel 9 series — is the smartest mobile OS out there, at least when it comes to protecting users from scams and digital fraud. With Gemini deeply integrated everywhere and new capabilities like Project Astra changing how we interact with a phone, what you get is a one-of-a-kind experience. Of course, all that AI chatter doesn't mean the Pixel 9 gets the basics wrong. The battery life is reliable and I never had to pull my power bank mid-way through the day. It's not the fastest charging phone out there, but the competition from Samsung or Apple isn't doing anything dramatically better despite the high asking price. I haven't run into any glaring call or network reception issues yet, so there's that assurance. The camera experience continues its hot streak. And thanks to Android 16's optimizations, there are more granular controls to compose the frame. Portraits turn out fantastic, and night mode shots continue to wow on Google's entry-point flagship phone. The overarching theme with the Pixel 9 is that it has matured a lot, especially after the Android 16 update. And at its current asking price of $799, it doesn't miss a beat where you can outright reject it. On the contrary, it gives pricier Androids and iPhones a run for their money. If it's reliability you seek from your phone, the Pixel 9 has truly evolved in that parameter. And if you see a deal on this one, grab it to sweeten the experience.
